As a neurodegenerative disease, early diagnosis of Alzheimer's disease (AD) is essential for delaying the progress of the disease. Due to the limitations of diagnostic methods, new biomarkers and detection technologies are urgently needed. Therefore, this paper mainly discusses the research and development of specific antibodies by lymphocyte hybridoma technology and the application of proximity extension assay (PEA) methodology in the field of in vitro diagnosis (IVD) for early screening detection of AD [1]. By applying Olink proteomic analysis technology with PEA methodology, the potential value of Olink proteomic analysis technology in improving the diagnostic accuracy and early identification of AD is clearly explained, which provided new ideas for future research direction and clinical application.
No takes yet. Share an insight, caveat, or question.
R. Li Zhu (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: